However, not only is TAM treatment not a valid option for groups 3 and 4 because there is no ER expression in these tumours, but non-luminal breast cancers are more aggressive, offer a poorer prognosis, and respond to fewer treatment options [8, 10]. This evidence concerns the gene ESR1 and breast cancer.